The present study describes the synthesis and pharmacological profile of three novel heterocyclic compounds originally designed, on the basis of bioisosterism, as dopamine D2 receptor ligands: 1-[1-(4-chlorophenyl)-1H-pyrazol-4-ylmethyl]-4-phenyl-piperazine (LASSBio-579), 1-phenyl-4-(1-phenyl-1H-[1, 2, 3] triazol-4-ylmethyl)-piperazine (LASSBio- 580) and 1-[1-(4-chlorophenyl)-1H-[1, 2, 3] triazol-4-ylmethyl]-4-phenyl-piperazine ( ...